Paliperidone palmitate - Johnson & Johnson

Drug Profile

Paliperidone palmitate - Johnson & Johnson

Alternative Names: Invega Sustenna; Invega Trinza; Paliperidone palmitate long-acting injection; R0-92670; RO-92670; Sustenna; Trevicta; Xeplion

Latest Information Update: 10 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Johnson & Johnson
  • Developer Janssen Pharmaceutical KK; Johnson & Johnson; Xian-Janssen
  • Class 2 ring heterocyclic compounds; Antipsychotics; Fluorobenzenes; Isoxazoles; Piperidines; Pyrimidinones; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Schizoaffective disorder; Schizophrenia

Most Recent Events

  • 26 Mar 2018 Janssen-Cilag completes a phase III trial in Schizophrenia in France, Malaysia, Spain, the UK, Germany, Netherlands, Denmark, Greece, Croatia, Israel, South Korea, Russia, Saudi Arabia, Taiwan, Turkey (IM) (NCT02713282)
  • 03 Jan 2018 Updated efficacy and adverse events data from the phase IV PRIDE trial in Schizophrenia released by Janssen Pharmaceuticals
  • 03 Jan 2018 The US FDA approves an sNDA for the product label to include real-world data from the phase IV PRIDE trial in Schizophrenia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top